Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) reported on its clinical trials and financial performance for the fiscal year ending April 30, 2022. Key updates include ongoing enrollment in the KONFIDENT Phase 3 trial for sebetralstat and KVD824's KOMPLETE Phase 2 trial. The company received EU Orphan Drug status for sebetralstat, promising 10 years of market exclusivity. Financially, KalVista recorded a net loss of $82.3 million for the fiscal year, up from $46.2 million the previous year, largely due to increased R&D costs. The cash position stood at $166.2 million.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement stock options to two newly-hired employees, totaling 8,000 shares with an exercise price of $9.90 per share. This price corresponds to the stock's closing price on July 1, 2022. The options vest over four years, beginning with a one-year cliff, and have a 10-year term.

KalVista focuses on developing oral protease inhibitors for unmet medical needs, targeting conditions like hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals (NASDAQ: KALV) presented promising data on its oral plasma kallikrein inhibitor, sebetralstat, and oral Factor XIIa inhibitor at the EAACI2022 conference in Prague. Sebetralstat demonstrated effective relief in 80% of acute attacks within 12 hours, unaffected by meal timing. Preclinical results for KV998086 showed potential for once-daily prophylaxis against hereditary angioedema (HAE). The population pharmacokinetic study broadens treatment possibilities for adolescents without dose adjustments, enhancing the company’s positioning for future trials.

KalVista Pharmaceuticals (NASDAQ: KALV) has announced the acceptance of multiple abstracts for presentation at the 2022 EAACI Congress in Prague, taking place from July 1-3, 2022. Key presentations include:

• Identification of potent oral Factor XIIa inhibitors by Allen C. Clermont, discussing angioedema.
• Efficacy of Sebetralstat in a Phase 2 clinical trial by Emel Aygören-Pürsün.
• Efficacy and Safety of Sebetralstat in a Phase 3 study by Andrea Zanichelli.
• Population Pharmacokinetic Analysis of KVD900 by Sinisa Savic.

KalVista focuses on oral protease inhibitors for diseases like hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals (NASDAQ: KALV) showcased significant advancements at the KININ2022 conference, presenting promising preclinical data on oral Factor XIIa inhibitors, which block the kallikrein kinin system (KKS) in disease models. CEO Andrew Crockett highlighted these inhibitors as potential treatments for hereditary angioedema (HAE). KalVista also shared data on sebetralstat, an oral therapy for acute HAE attacks, currently in Phase 3 KONFIDENT trial. The company aims to improve patient outcomes in KKS-related diseases with its innovative therapies.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the grant of inducement options to a newly-hired employee for 20,000 shares of common stock on June 1, 2022. The options have an exercise price of $8.74, matching the closing share price on the grant date. They vest over four years, with one-fourth vesting on the one-year anniversary, followed by monthly vesting. This grant complies with Nasdaq Listing Rule 5635(c)(4). KalVista is focused on developing oral protease inhibitors for unmet medical needs, including treatments for hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company, will present at the 13th Annual Jefferies Global Healthcare Conference on June 8, 2022, at 11:30 a.m. ET. The presentation will focus on its pipeline of small molecule protease inhibitors, including sebetralstat and KVD824, targeting hereditary angioedema and diabetic macular edema. A live webcast will be available on the company’s website, with an audio archive accessible for 30 days post-event.

KalVista Pharmaceuticals (NASDAQ: KALV) announces the immediate appointment of Patrick A. Treanor to its Board, as part of a planned transition, succeeding Dan Soland, who has resigned. Treanor, currently COO of Pathalys Pharma, brings extensive experience in sales and marketing within the biopharmaceutical sector. His expertise is seen as vital for KalVista's evolution towards a pre-commercial phase, focusing on FDA approval and commercialization of key therapies, including sebetralstat and KVD824.

KalVista Pharmaceuticals has received approval for its drug candidate, sebetralstat, from the WHO and USAN. This medication is currently undergoing evaluation in a Phase 3 study named KONFIDENT, targeting on-demand treatment for hereditary angioedema (HAE) attacks. CEO Andrew Crockett expressed enthusiasm for sebetralstat's potential to be a groundbreaking oral therapy for HAE. The company is actively preparing for future regulatory submission while progressing with its ongoing clinical trials for sebetralstat and another drug, KVD824.